Welcome to our dedicated page for Lyra Therapeutics SEC filings (Ticker: LYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech can feel as complex as its science. Lyra Therapeutics’ SEC disclosures weave together XTREO platform chemistry, clinical trial milestones, and funding needs—information scattered across 200-page 10-K reports and surprise 8-K material event notices. Locating the right data points before the market reacts is a genuine challenge.
Stock Titan solves it. Our AI parses every Lyra Therapeutics quarterly earnings report 10-Q filing, extracts CRS pipeline costs, and charts cash runway in seconds. You’ll receive Lyra Therapeutics Form 4 insider transactions real-time, so shifts in executive stock transactions never slip past you. Plain-English overviews sit on top of every document, allowing understanding Lyra Therapeutics SEC documents with AI instead of wading through technical jargon.
Ask naturally—“How to read Lyra Therapeutics annual report 10-K simplified” or “Show me Lyra Therapeutics proxy statement executive compensation”—and the platform delivers direct answers plus the source filing. Alongside AI-powered highlights you’ll find:
- Lyra Therapeutics insider trading Form 4 transactions with drill-downs by officer
- Side-by-side Lyra Therapeutics earnings report filing analysis across quarters
- Instant alerts for Lyra Therapeutics 8-K material events explained in plain language
- Downloadable sections for due-diligence models
Whether you monitor dilution risk before a capital raise or verify CRS study endpoints, every Lyra Therapeutics SEC filing is updated the moment EDGAR posts. Complex biotech narratives, simplified: that’s our promise.
Maria Palasis, President & CEO and a director of Lyra Therapeutics, Inc. (LYRA), reported a change in beneficial ownership after the company determined on 10/01/2025 that Milestone 2 under a performance stock option (PSO) award was achieved. The PSO grant, originally made on 03/21/2024, covered up to 11,000 shares; 3,667 PSOs were earned as a result of Milestone 2. Those earned PSOs are exercisable under the award terms and will vest on 01/31/2028. Following the reported transaction, the filing shows 7,333 shares of common stock beneficially owned directly by the reporting person. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Palasis and dated 10/03/2025.
Lyra Therapeutics reported receipt of a Nasdaq deficiency letter because its stockholders' equity was approximately $1.6 million as of June 30, 2025, below the Nasdaq Capital Market minimum requirement of $2.5 million. The filing states the deficiency letter has no immediate effect on the listing or trading of the company's common stock, which will continue to trade on Nasdaq under the symbol LYRA. The company points investors to its Annual Report and Quarterly Report for risk disclosures and reiterates standard forward-looking statements caution. The report is dated August 22, 2025, and signed by CFO Jason Cavalier.
Perceptive Advisors and related parties report a 15.55% beneficial stake in Lyra Therapeutics. The Schedule 13D/A discloses ownership of 255,750 shares of Lyra common stock out of 1,644,454 shares outstanding as reported in the filing. Ownership is held collectively by Perceptive Advisors LLC and affiliated entities: Perceptive Life Sciences Master Fund, Ltd. (229,982 shares, 13.99%) and Perceptive LS (A), LLC (25,768 shares, 1.57%). The cover pages show shared voting and dispositive power over the reported shares and identify the source(s) of funds as stated in the filing. The filing provides a clear ownership breakdown and the percentage calculations based on the issuer's reported outstanding shares.
Lyra Therapeutics reported mixed clinical and financial results for the quarter. The company announced positive Phase 3 ENLIGHTEN 2 results for LYR-210, showing statistically significant improvement versus sham in the three-cardinal-symptom composite (3CS) at 24 weeks in patients without nasal polyps (treatment effect -1.13; p=0.0078), in the full population (-0.90; p=0.0209), and in SNOT-22 score (-8.7; p=0.0101). LYR-210 was generally well tolerated with no product-related serious adverse events.
On the financial side, Lyra had $29.8 million in cash and cash equivalents at June 30, 2025 and an accumulated deficit of approximately $420.8 million. Net loss was $7.4 million for the quarter and $16.0 million for the six months ended June 30, 2025. The company completed a June 2025 financing that raised $5.0 million gross ($4.3 million net) and sold shares under its shelf registration generating $26.7 million of proceeds (net). Following an earlier failed Phase 3 ENLIGHTEN 1 trial and related cost reductions (including a workforce reduction of 87 employees and impairment charges), management disclosed substantial doubt about its ability to continue as a going concern and has paused commercialization and certain development and manufacturing activities while pursuing strategic and cost-saving actions.
Lyra Therapeutics filed an 8-K reporting it announced financial results for the quarter ended June 30, 2025. The filing states the company furnished a press release as Exhibit 99.1 and posted a corporate presentation on its website, furnished as Exhibit 99.2. Both exhibits are expressly described as "furnished, and not filed," and the company disclaims any obligation to update the presentation. The filing identifies Lyra's common stock as trading under the symbol LYRA on The Nasdaq Capital Market and indicates the company is an emerging growth company. The report is signed by CFO Jason Cavalier on August 12, 2025.
FAQ
What is the current stock price of Lyra Therapeutics (LYRA)?
What is the market cap of Lyra Therapeutics (LYRA)?
